Reuters logo
BRIEF-VBL therapeutics Q3 loss per share $0.24
November 14, 2017 / 12:20 PM / 10 days ago

BRIEF-VBL therapeutics Q3 loss per share $0.24

Nov 14 (Reuters) - Vascular Biogenics Ltd

* VBL Therapeutics announces third quarter 2017 financial results

* Q3 loss per share $0.24

* Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S

* Vascular Biogenics Ltd - ‍ remain on-track to initiate a phase 3 study of vb-111 in ovarian cancer by year-end 2017​

* Vascular Biogenics Ltd - ‍ also planning an exploratory clinical study in combination with a checkpoint inhibitor in lung cancer in q1 of 2018​

* Vascular Biogenics - ‍expect cash, cash equivalents, short-term bank deposits to enable funding operating expenses and capex requirements through 2019​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below